I
nfluenza infection is a significant cause of morbidity and mortality, affecting 5% to 10% of the population of the United States annually, and accounts for an annual mortality rate of 22.2 per 100,000 individuals. 1 It is responsible for 226,000 hospitalizations each year, and an annual economic burden of $87.1 billion. 2 People over the age of 65 and those who are immunosuppressed, particularly those with cancer, are especially susceptible. 3 Cancer is a disease of the elderly, with the median age at diagnosis being 67 years per statistics reported by Surveillance Epidemiology and End Results. Influenza infection leads to delays and interruption of chemotherapy and may necessitate hospitalization. 3, 4 Trivalent inactivated influenza vaccine (IIV3) is the most common vaccine formulation administered. 2 Memory B and T cells are formed in the setting of vaccination, which allows the adaptive immune system to respond when challenged with pathogen exposure, in a process that can take up to 2 weeks for healthy patients. 5 Prospective studies demonstrate the inactivated influenza vaccine to have 70% to 90% efficacy in preventing influenza infection in healthy young adults when a good match exists between the vaccine and epidemic virus. 6 The trivalent vaccine is almost universally well tolerated. Transient symptoms may include, but are not limited to, local muscle soreness, myalgias, arthralgias, and fever. 7 Hemagglutination inhibition (HI) is the universally accepted assay for quantifying serological response to the vaccine in the research setting.
Response to vaccination relies on an intact immune system that can produce antibodies in response to antigen exposure. Individuals with cancer, however, often have immune deficiencies as a result of their disease and/or immunosuppressive therapies. 3 Misconceptions among both patients and physicians about the benefits of the vaccine in these patients, including concern about safety and side-effect profiles, may hinder timely administration of the vaccine. 3 There is prospective evidence to suggest that fewer than 50% of adult patients with cancer undergoing chemotherapy receive the influenza vaccination. 8, 9 The optimal timing for administration of influenza vaccination in patients with cancer receiving chemotherapy is not clear. Although myelosuppression from chemotherapy is transient, it is unknown whether there would be any long-term effect on lymphoid cells. Newer data investigating humoral responses to influenza vaccination in patients with lymphoma treated with rituximab suggest that therapies that deplete B cells impair patients' ability to achieve protective immunity. 10 It is possible, but unproven, that cumulative effects from repeated cycles of cytotoxic chemotherapy may dampen the response to influenza vaccination. Also, steroid use as premedication around the time of chemotherapy may dampen the immune response, and vaccinating in between chemotherapy cycles may be a better approach. Understanding the appropriate timing of the influenza vaccination in relation to chemotherapy would facilitate optimal protection of patients with cancer from the morbidity and mortality associated with influenza infection in patients with cancer.
The very few studies that have evaluated seroprotection in response to influenza vaccination in patients with cancer were conducted several years ago. [11] [12] [13] [14] There have been significant changes in the types and schedules of cytotoxic chemotherapy regimens used in the treatment of cancer over the past 2 decades. We believe that only a prospective randomized study can systematically address the efficacy of influenza vaccination in patients with cancer using modern day chemotherapy regimens, and the optimal timing of administration of influenza vaccine in relation to chemotherapy. We therefore performed this pilot study to determine the optimal timing of seasonal influenza vaccination with regard to chemotherapy administration schedule, to provide preliminary data for an adequately powered randomized prospective study.
MATERIALS AND METHODS

Study Participants
Adult patients (aged 18 y and above) with nonhematological malignancies receiving cytotoxic chemotherapy in the oncology outpatient clinics at the Alvin J. Siteman Cancer Center, St. Louis, Missouri were invited to participate in this study, during the 2011 to 2012 influenza season. Institutional review board approval was obtained and subjects provided written informed consent for vaccination and for blood collection for HI assays at baseline and 4 weeks postvaccination. Patients were eligible if they were receiving cytotoxic chemotherapy either on an every 2 or 3 week schedule, and individuals receiving weekly chemotherapy were excluded, as were patients receiving radiation therapy. Patients receiving immunotherapy, history of immunosuppression, history of human immunodeficiency virus or organ transplantation, chronic steroid therapy (Z14 d, though steroids used as part of chemotherapy regimen were allowed), and individuals with absolute lymphocyte count (ALC) <1.0 K/ cumm were excluded. Patients were also excluded if they had already received the influenza vaccine during that season, or had contraindications to influenza vaccination such as allergic reaction to influenza vaccine or egg allergies, history of Guillian-Barre syndrome. Patients with active infection or history of influenza-like illness defined as temperature >37.81C 
Study Design
The 
Immunogenicity Assessment
The samples were sent to Saint Louis Center for Vaccine Development, St. Louis, Missouri. Prevaccination susceptibility and postvaccination serological responses were assessed by HI assay. Seroprotection (HI antibody titers postvaccination Z1:40) and seroconversion (a 4-fold rise in titers from before vaccination) were used as measures of protective immunity. Reciprocal HI titers of Z40 were considered protective, corresponding to an approximately 50% decrease in influenza infection risk. Geometric mean titers (GMTs) for the HI assay at baseline and at 4 weeks were also calculated.
Statistical Analysis
As a pilot study, the data analysis was descriptive in nature. Demographic and clinical characteristics of the sample were summarized using descriptive statistics. The differences in seroprotection rates and seroprotection rates between the 2 groups were summarized using contingency tables and compared by Fisher exact test. The changes in the HI assay from baseline to 4 weeks as well as the differences between groups were also compared using nonparametric signed rank test and Mann-Whitney rank-sum test, respectively. All the analyses were performed using SAS 9.2 (SAS Institutes, Cary, NC).
RESULTS
Demographics
A total of 42 patients with solid tumors scheduled to receive chemotherapy were consented for this study between September 29, 2011 and November 14, 2011. We excluded 14 patients due to low ALC, 1 patient was ineligible due to chronic steroid use, an additional patient was ineligible due to chemotherapy being delayed for nonprotocol reasons, and 2 patients withdrew consent. An additional 5 patients were excluded from this study as paired blood samples (baseline and 4 wk postvaccination) were not available. This resulted in a total of 18 patients who met all eligibility criteria, and hence were registered to the study and were included in the final analysis. Eight patients were vaccinated on schedule A, whereas 10 patients were vaccinated on schedule B. Baseline and 4 weeks postvaccination blood samples were collected from all 18 participants. Table 1 describes the demographics of the study subjects. The median age of participants was 56.8 years (range, 42.5 to 70.6 y), most were of white race (13/18) and half of the participants were of male sex (9/18). Seven participants had pancreatic cancer, 1 had liver cancer, 5 had colorectal cancer, 4 had lung cancer, and 1 patient had sarcoma. All patients enrolled in this study had received prior chemotherapy, with a median of 3 cycles of prior chemotherapy (range, 1 to 12 cycles). Table 1 describes the specific chemotherapy regimens they had received.
Overall Immunogenicity of Influenza Vaccine
Seroconversion against the H1N1, H3N2, and B strains was observed in 55.5% (10/18), 61.1% (11/18), and 50% (9/ 18) of patients, respectively. Before vaccination, 33.3% (6/18) patients demonstrated seroprotection against any 1 strain, but none of them showed seroprotection to 2 or more strains. Specifically, 0% (0/18), 11.1% (2/18), and 22.2% (4/18) of patients had seroprotective antibody titers (Z1:40) against H1N1, H3N2, and B, respectively. After vaccination, seroprotective antibody titers were observed, respectively, in 33.3% (6/18), 44.4% (8/18), and 50% (9/18) of patients against H1N1, H3N2, and B. 
Immunogenicity in Relation to Timing of Chemotherapy
Seroconversion to at least 1 strain was observed in 75% (6/8) of patients vaccinated on schedule A, and 70% (7/10) of patients vaccinated on schedule B. Seroconversion to all 3 strains was observed in only 25% (2/8) and 40% (4/10) of patients, respectively. Seroconversion against H1N1, H3N2, and B strains was observed in 63% (5/8), 50% (4/8), and 38% (3/8) of participants vaccinated on schedule A, and 50% (5/10), 70% (7/10), and 60% (6/10) on schedule B (Table 2 ). There was no statistically significant difference in seroconversion rates among patients vaccinated on the 2 schedules for any of the 3 influenza virus strains, based on the Fisher exact test.
Seroprotection rates were also assessed for groups A and B. All of the patients (8/8) vaccinated on schedule A demonstrated seroprotection to at least 1 strain, compared with 60% (60%) of patients vaccinated on schedule B. Seroprotection rates were 50% for all 3 strains in the schedule A group, and in the schedule B group they were 20% (2/10), 40% (4/10), and 50% (5/10) for strains H1N1, H3N2, and B, respectively (Table 3) . GMTs against each strain did significantly improve in patients in both groups following influenza vaccination, based on the signed rank test (Table 4) . However, no significant difference was found in postvaccination GMTs between schedules A and B after adjusting the prevaccination titers, based on Mann-Whitney U tests (Table 3) .
DISCUSSION
Our study demonstrates that patients with solid tumors undergoing chemotherapy respond to trivalent influenza vaccination when receiving modern day cytotoxic chemotherapy regimens. Previous studies date back to the 1970s, and included both patients with hematologic malignancies and solid tumors (Table 5) . 4, 11, 15, 16 They also differed in respect to time points at which titers were drawn, and most looked at the primary endpoint of seroconversion only.
Seroprotection is a more clinically important endpoint than seroconversion, since even if a patient responds to the vaccine with a 4-fold increase in titers that may still not result in seroprotection (titers of 1:40) if the immune response is not as robust. Seroprotection with titers of 1:40 is generally held as the objective measure of protection against the influenza virus. Anderson et al 12 examined the seroprotection rates in 59 patients with lung cancer who received influenza vaccination, and found a seroprotection rate of 83%. However, only 14 of the patients enrolled in this study had received chemotherapy in the previous month, and therefore these results cannot be generalized to patients receiving chemotherapy.
Our study is unique in several regards. First, it specifically examined the immunogenicity of influenza vaccination in patients with nonhematologic solid tumors who are receiving chemotherapy, whereas previous studies also included patients with cancer who were not receiving chemotherapy, patients with chronic steroid use, and patients with low ALC who may not mount a sufficient immune response. Second, endpoints included seroprotection, which may be more clinically meaningful. Finally, this study examines the question of whether the timing of vaccination in regards to chemotherapy administration impacts vaccination response. The only other study that has examined the timing of vaccination was performed by Ortbals et al 4 at our institution almost 4 decades ago and demonstrated superior seroconversion rates in patients vaccinated in between chemotherapy cycles, rather than on day 1 of chemotherapy. Their study included patients with both hematologic and nonhematologic malignancies, over a quarter of whom had ALC < 500 cells/mm 3 . In addition, 30% of these patients were receiving systemic corticosteroids. We purposefully excluded patients with other confounding factors such as ALC < 1000 cells/mm 3 and immunosuppression from steroids to specifically address the impact of chemotherapy. Our study did not corroborate the findings of improved response to vaccination in patients vaccinated between chemotherapy cycles, possibly due to differences in the study population.
Limitations of our study include a small sample size, which makes it difficult to generalize the findings to all solid tumors, as none of the participants had cancers of the breast, genitourinary tract, central nervous system, and melanoma. Furthermore, not all modern chemotherapy regimens in use were represented. Nevertheless, this study serves as pilot data for the design of an adequately powered prospective study, with patients stratified by cancer type and types of chemotherapy regimens.
Timing of influenza vaccination in relation to chemotherapy for these 2 time points studied does not seem to change the seroconversion and seroprotection rates. Regardless of timing in relation to chemotherapy, patients did mount an immune response to the vaccine. Given the significant morbidity and mortality posed by influenza infection in patients with cancer, the best defense is prevention by vaccination. This should universally be offered promptly to all patients with no contraindication.
CONCLUSIONS
Patients with nonhematological malignancies who are receiving chemotherapy mount an immune response to influenza vaccination. Timing of influenza vaccination in relation to chemotherapy does not seem to matter.
